Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

UNCOVERED: Ro - Caught on Camera

Serena Williams confirms stunning return to tennis ahead of Wimbledon at age of 44

Williams will begin her ‘next chapter’ by playing doubles at Queen’s Club, ahead of possibly competing in singles at Wimbledon

The Independent UK

RFK Jr.'s peptide push could become next wellness boom

The heavily touted but loosely regulated proteins could fuel the kind of boom we've seen with weight-loss drugs.

Axios

Tennis Mailbag: What a Potential Serena Williams Comeback Could Look Like

The 44-year-old has been coy about a possible return to the sport despite her name appearing on the ITIA’s reinstatement list.

Sports Illustrated

From analysis to the latest developments in health,
read the most diverse news in one place.

Serena Williams Slammed Over ‘Disgusting’ Super Bowl Ad Amid Controversial Weight Loss Transformation

“Why is she doing that with all the money in the bank; how sad is that for a famous woman.”

Bored Panda

George Clooney and Kendall Jenner to feature in Super Bowl ads as off-field battle heats up

Over 120 million viewers will tune in for this weekend’s Super Bowl between the Seattle Seahawks and the New England Patriots

The Independent UK

“The Knees Are Kneeing”: Serena Williams Leaves Fans Stunned With Viral Jaw-Dropping Move

“I ain’t sorry, these Meg knees are here to stay,” Serena Williams wrote

Bored Panda

Novo Nordisk Is Getting a Major Boost from Amazon for Its New Wegovy Pill. Does That Make NVO Stock a Buy Here?

Novo Nordisk shares inch higher as the pharma giant announces an oral Wegovy partnership with Amazon Pharmacy. Here’s why NVO stock is worth owning at current levels.

Barchart

Read news from The Economist, FT, and more,
with one subscription

'I've seen so many doctors' - Thalita de Jong looking forward to 2026 after year plagued by medical mystery

Former cyclocross world champion aiming for incident free season with Human Powered Health

Cycling News

Soft2Bet fuses social media and iGaming experience in Romania

Swiper brings social media-style betting.

Dot Esports

Heated Reactions After Serena Williams Calls Out NYC Hotel Over Cotton Plant Decoration

"How do we feel about cotton as decoration?" the tennis star asked her followers.

Bored Panda

How do weight loss jabs work? Dr Amir Khan reveals all you need to know

Whether you know Mounjaro from Wegovy or it's all Ozempic to you, you'd have to be living (blissfully) under a rock to miss the chatter about weight loss jabs

Woman & Home

Jameela Jamil slams Serena Williams over weight-loss medication use

Jameela Jamil finds it "uncomfortable" seeing Serena Williams promote the use of weight-loss medication.

BANG Premier

Voices: Serena Williams’s GLP-1 partnership marks a disturbing cultural turning point

COMMENT: As a Black woman in a white-dominated sport, Williams experienced unique pressures. Yet to see someone of her calibre promoting weight-loss drugs shows an unnerving societal shift, writes the body image campaigner Alex Light

The Independent UK

Serena Williams built her legacy on defiance. Why lend it to Ozempic culture?

From Compton outsider to American nonpareil, she came to embody resistance. But her embrace of GLP-1 drugs feels like capitulation to ideals she once rejected

The Guardian - US

Get all your
news in one place.

100's of premium titles.
One news app.

Euronews

Serena Williams reveals GLP-1 treatment helped her lose 31 pounds after giving birth

After years of struggling with postpartum weight gain despite strict training and healthy eating, the 23-time Grand Slam champion turned to a GLP-1 medication.

Marie Claire

Serena Williams's Take on Fall 2025's Wide-Leg Trouser Trend Belongs in the US Open Stands

She served an off-court look miles away from the tennis courts.

Marie Claire

Serena Williams Being Open About Using a GLP-1 Is Exactly the News I Wanted to See Today

The weight loss conversation is shifting.

Benzinga

From Taboo To Tech: Fellow Health's $24M Raise Signals Big Shift In Men's Reproductive Health

Fellow Health just raised $24 million in a Series B funding round, bringing its cash haul across multiple offerings to $48 million. The San Leandro, California startup advances male reproductive health through "patient-centric testing solutions" and plans to use the capital infusion to expand its mail-in semen analysis services.

Get all your
news in one place.

100's of premium titles.
One news app.

Al Jazeera

Folk music and raids: How ultranationalists target migrants in Russia

The Russian Community group has soared in popularity, with its focus on promoting the needs of ‘ethnic Russians’.

International Business Times UK

Why Did Novo Nordisk Pull the Plug on Hims Collaboration?

Novo Nordisk ended its partnership with Hims & Hers on 23 June 2025, accusing the telehealth firm of selling unsafe, unapproved Wegovy knock-offs. Hims' stock tanked, and legal risks loom.

The Independent UK

You might soon be able to get Wegovy from an online shop — here is where you need to visit

The move comes as Danish drugmaker Novo Nordisk has acted to slash the popular weight loss drug’s price

The Times of India

SAI, World Boxing appoint independent observers for BFI elections

NEW DELHI: Acting on the Himachal Pradesh High Court's order, the government has appointed Sports Authority of India’s (SAI) deputy director general in the Khelo India division, Mayank Srivastava, as an ‘independent observer’ to scrutinise the conduct of the much-delayed Boxing Federation of India (BFI) elections. World Boxing has also…

The Independent UK

Take it from locals: Super experience in New Orleans entails more than just the French Quarter

New Orleans chef Susan Spicer has been a regular contributor to the Taste of the NFL charity event at Super Bowl host cities around the country and is doing so in her hometown again this year

Fortune

As more and more weight-loss startups prescribe Ozempic and Wegovy, doctors say they’re making unproven claims

Noom, Calibrate, and Embla tell customers they can stop taking GLP-1s and keep off the weight they’ve lost. Doctors and drug manufacturers disagree.

Fortune

These weight-loss startups tell customers they can stop taking Ozempic or Wegovy and stay thin. Doctors disagree

As nearly $1 billion of venture capital dollars have been injected into weight-loss startups since 2023, companies are making unproven claims to attract customers. It’s a new twist on a story as old as the diet industry.

1 2 3

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.